Section Arrow
CRDL.NASDAQ
- Cardiol Therapeutics
Quotes are at least 15-min delayed:2026/03/28 18:46 EDT
Regular Hours
Last
 1.25
+0.14 (+12.61%)
Day High 
1.29 
Prev. Close
1.11 
1-M High
1.125 
Volume 
3.38M 
Bid
1.15
Ask
1.2
Day Low
1.09 
Open
1.1 
1-M Low
0.89735 
Market Cap 
123.96M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.02 
20-SMA 1.02 
50-SMA 1.02 
52-W High 1.59 
52-W Low 0.7709 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.41/-0.44
Enterprise Value
124.09M
Balance Sheet
Book Value Per Share
0.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health19.38-1.48-7.09%40.92PE
HLNHaleon plc9.8+0.05+0.51%19.79PE
TEVATeva Pharmaceutical Industries Limited28.74-1.04-3.49%24.64PE
ELANElanco Animal Health23.13-1.45-5.90%355.43PE
VTRSViatris13.05-0.32-2.39%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.